

**ASHP Midyear Clinical Meeting 2014  
Anaheim, CA**

**Sunday, December 7, 2014**

**Resuscitation Trifecta: Trauma, Cardiac Arrest and Sepsis**

**Sunday, December 7, 2014**

**8:15 AM – 9:15 AM**

Activity #0204-0000-14-310-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Platinum 5, Anaheim Marriott

Presenters: Scott Micek, PharmD; Asad Patanwala, PharmD, BCPS; Chris Wood, PharmD

**Learning Objectives:**

- Recommend optimal drug-therapy during resuscitation.
- Evaluate evidence for the selection of pharmacological agents during resuscitation.
- Provide practical tips for practitioners responding to resuscitations.

**Emergency Medicine Networking Sessions**

**Sunday, December 07, 2014**

**12:30 PM - 1:30 PM**

Room: 203A, Level 2

Facilitator: Megan Musselman, PharmD, MS, BCPS

**Discussion Topics:**

- Discussion regarding the pros and cons for emergency pharmacists having their own board certification
- Activities of pharmacists in different hospital settings (community vs academic) including experiences precepting students and residents in these settings
- PCC preparation, protocols and administration (who, how and where)
- Push-Dose Pressors (safety vs utility; logistics for dispensing, preparation, etc) and Ketofol preparation/dispensing, administration (single syringe vs separate syringes and safety/security implications)
- The good, the bad and the ugly of research in the ED: opportunities, challenges, and success stories

**No IV, No Problem! Practical Approaches to Alternate Routes of Administration**

**Sunday, December 7, 2014**

**1:00 PM – 3:00 PM**

Activity #0204-0000-14-315-L01-P

Level of Content: General Interest

2.00 Contact Hours/Application-based

Room: Platinum 6, Anaheim Marriott

Presenters: Joseph Halfpap, PharmD, BCPS; Christi Jen, PharmD, BCPS, Laurimay Laroco, PharmD, Suprat Wilson, PharmD, BCPS

**Learning Objectives:**

- Evaluate the need for alternative routes of drug administration.
- Describe proper technique and identify medications appropriate for intranasal administration.
- Evaluate the risks and benefits with drug administration via intraosseous route.
- Recommend appropriate medications, doses, and techniques for endotracheal tube administration.
- Recommend appropriate techniques, fluids, and adjunctive agents for hypodermoclysis.

## **Management Case Study: Implementation of a Pharmacist-Driven First-Dose Counseling, Discharge Medication Reconciliation, and Discharge Counseling Program to Improve Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Performance**

**Sunday, December 7, 2014**

**1:00 PM – 1:30 PM**

Activity #0204-0000-14-283-L04-P

Level of Content: General Interest

0.50 Contact Hours/Knowledge-based

Room: 209A, Level 2

Presenter: Erick Sokn, PharmD, MS, BCPS

### **Learning Objectives:**

- Describe the benefits of implementing discharge counseling versus first dose counseling.
- Identify important process and outcome measures for a pharmacist counseling program.
- Describe a method of identifying target populations for first-dose counseling.

## **Management Case Study: If a First You Don't Succeed: Overcoming Obstacles When Establishing Transitions of Care Pharmacy Services**

**Sunday, December 7, 2014**

**1:45 PM – 2:15 PM**

Activity #0204-0000-14-284-L04-P

Level of Content: General Interest

0.50 Contact Hours/Knowledge-based

Room: 209A, Level 2

Presenters: Laura Carr, PharmD

### **Learning Objectives:**

- Describe the opportunities for pharmacy involvement in improving patient outcomes at the time of discharge.
- Define some of the potential barriers to establishing and expanding transitions of care pharmacy services.
- Compare the effectiveness of a pre-discharge versus a post discharge pharmacist intervention at a large academic medical center.

## **Alice in Toxicland: Case-Based Treatment and Transitions of Care for Hallucinogen, Stimulant, and Depressant Overdoses**

**Sunday, December 7, 2014**

**2:45 PM – 3:45 PM**

Activity #0204-0000-14-316-L01-P

Level of Content: Intermediate

1.00 Contact Hours/Application-based

Room: Platinum 5, Anaheim Marriott

Presenters: Megan Corrigan, PharmD; Phillippe Mentler, PharmD, BCPS

### **Learning Objectives:**

- Identify new hallucinogens and describe treatment for overdose situations.
- Summarize the treatment for overdose situations of stimulants.
- Explain the treatment for overdose situations for opiates and depressant drugs

## **Infectious Diseases Networking Sessions**

**Sunday, December 7, 2014**

**2:30 PM-3:30 PM**

Room: 203A, Level 2

Facilitator: Nicole Bolton, PharmD

### **Discussion Topics:**

- Rapid pathogen detection using molecular technology and incorporating into an ASP
- Formalizing an ASP in a small community hospital
- Development of basic antibiotic competencies and training for staff pharmacists

## **Pharmacist Coordinated Acute and Chronic Community Health Care Delivery Models: Transitions of Care Success Stories and Lessons Learned**

**Sunday, December 7, 2014**

**1:45 PM – 2:15 PM**

Activity #0204-0000-14-302-L04-P/0204-0000-14-302-L04-T

Level of Content: General Interest

1.50 Contact Hours/Knowledge-based

Room: 209A, Level 2

Presenters: David Harlow, BS, PharmD; William Lee, DPh, MPA; Gary Matzke, BSP Pharm, PharmD; Leticia Moczygemba, PharmD, PhD

### **Learning Objectives:**

- Describe two best practices to manage patient transitions of care.
- State the three points in the continuum of care that can improve patient outcomes.
- Differentiate between process and health outcomes evaluation metrics.

## Monday, December 8, 2014

### **Opening Session and Keynote**

**Monday, December 8, 2014**

**Speaker: Jay Leno**

**9:00 AM-10:30 AM**

Room: Arena, Level 1

Acclaimed TV late night show host, admired stand-up comedian, best-selling children's book author, and much-in-demand speaker, Jay Leno, will be the Keynote Speaker for the Midyear Meeting!

### **Ambulatory Care Practice Sections Network Sessions**

**Monday, December 8, 2014**

**12:30 PM-1:30 PM**

Room: 203A, Level 2

Facilitator: Binita Patel, PharmD, MS

#### **Discussion Topics:**

- How will ACOs/population health impact pharmacists who provide ambulatory care services?
- What are ambulatory care's major threats?
- Reimbursement – a constant challenge

### **Frequently Encountered Questions in Neurocritical Care**

**Monday, December 8, 2014**

**2:00 PM-3:30PM**

Activity #0204-0000-14-256-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Ballroom A, Level 3

Presenters: John Lewin, III, PharmD, MBA, FASHP; Kathryn Morbitzer, PharmD; Denise Rhoney, PharmD, FCCP; Anthony Rowe, PharmD, BCPS

#### **Learning Objectives:**

- Evaluate the optimal usage and monitoring of osmotic therapy for the management of cerebral edema.
- Discuss the preparation and administration of drugs directly into the central nervous system.
- Recommend strategies to reverse oral anticoagulant induced intracranial hemorrhage.
- Recommend indications that show benefit in utilizing antiepileptic drugs for seizure prophylaxis.

### **An Update on Uncommonly Used Antidotes**

**Monday, December 8, 2014**

**2:00 PM-3:30 PM**

Activity #0204-0000-14-258-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Ballroom C, Level 3

Presenters: Patrick Dougherty, PharmD, BCPS; Bryan Hayes, PharmD; Adrienne Perotti, PharmD, BCPS

#### **Learning Objectives:**

- Evaluate a medication therapy plan for managing a patient with sulfonylurea-induced hypoglycemia.
- Create a medication therapy plan for managing a patient with a calcium-channel blocker overdose.
- Determine a medication therapy plan for managing a patient with toxicological-induced cardiac arrest.

## **Safety & Quality Pearls 2014**

Monday, December 8, 2014

2:00 PM-4:00PM

Activity #0204-0000-14-200-L05-P/0204-0000-14-200-L05-T

Level of Content: General Interest

2.00 Contact Hours/Knowledge-based

Room: Ballroom B, Level 3

Program Chair/Moderator: Jennifer Robertson, Pharm.D., BCPS

### **Learning Objectives:**

- Describe three examples of interventions that have improved safety or quality of patient care in health systems.
- List steps for implementation of at least one safety improvement program.
- Explain how to apply three strategies for preventing patient harm.

## **Debates in Therapeutics 2014**

Monday, December 8, 2014

2:00 PM-4:00PM

Activity #0204-0000-14-205-L01-P

Level of Content: Advanced

2.00 Contact Hours/Knowledge-based

Room: 303B, Level 3

Program Chair: Sarah Bush, Pharm.D., BCPS

Moderator: Kevin E. Anger, Pharm.D., BCPS

### **Learning Objectives:**

- Explain why therapeutic controversies might occur in clinical practice.
- Identify three therapeutic areas in which controversies may exist.
- Discuss the pro and con arguments of selected therapeutic issues.

## **Professional Posters and ASHP Fellows**

Monday, December 8, 2014

2:30 PM-4:00 PM

Location: Hall E, Level 0 (Lower Level)

## **Stroke Care Plan from ED to ICU to Home - Where is your Pharmacist?**

Monday, December 8, 2014

4:15 PM-5:15 PM

Activity #0204-0000-14-213-L04-P

Level of Content: Intermediate

1.00 Contact Hours/Knowledge-based

Room: 210 B, Level 2

Presenters: Tony Casanova, PharmD; Aaron Steffenhagen, PharmD, BCPS

**Learning Objectives:**

- Describe the benefits a pharmacist is able to offer the "Stroke Team" and the specific areas of focus while responding to acute "Stroke Codes."
- Identify essential roles of a pharmacist in the overall management of anticoagulation during an ischemic stroke patient from door to discharge.
- Summarize the means for pharmacists to enhance stroke quality measure performance.

**Update in Therapeutic Hypothermia Post Cardiac Arrest**

Monday, December 8, 2014

4:15 PM-5:15 PM

Activity #0204-0000-14-259-L01-P

Level of Content: Advanced

1.00 Contact Hours/Application-based

Room: 201B, Level 2

Presenters: Allison Forni, PharmD, BCPS; Paul Szumita, PharmD, BCPS

**Learning Objectives:**

- Describe controversies on who, how, and when to initiate therapeutic hypothermia post cardiac arrest.
- Breakdown and evaluate the pharmacotherapy considerations for patients requiring therapeutic hypothermia.

## [Tuesday, December 9, 2014](#)

**Complexity at Its Best: Case-Based Approach to Management of Pain, Agitation and Delirium in the ICU**

Tuesday, December 9, 2014

8:00 AM-9:30 AM

Activity #0204-0000-14-265-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Ballroom D, Level 3

Presenters: Kevin Anger, PharmD, BPCS; John Devlin, PharmD; Giles Fraser, PharmD, MCCM

**Learning Objectives:**

- Evaluate recent literature on the management of pain, agitation, and delirium in the ICU.
- Discuss key concepts in the selection of sedatives, analgesics, and antipsychotic agents in critically ill patients.
- Appraise key barriers to optimizing pain, sedation, and delirium pharmacotherapy in critically ill patients.

## **Increase Pharmacy Documentation through Student and Resident Extenders**

Tuesday, December 9, 2014

9:00 AM-11:15 AM

Activity #0204-0000-14-282-L04-P

Level of Content: General Interest

1.25 Contact Hours/Application-based

Room: 210B, Level 2

Presenters: Christina DeRemer, PharmD, BCPS; Craig Martin, PharmD

### **Learning Objectives:**

- Discuss the Pharmacy Practice Model Initiative's emphasis on documentation of activities.
- Design methods for co-documentation of patient care activities.
- Explore methods to overcome barriers in your setting.

## **Demystifying Acute Management of Atrial Fibrillation**

Tuesday, December 9, 2014

9:30 AM-11:00 AM

Activity #0204-0000-14-268-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Platinum 5, Anaheim Marriott, Lobby Level

Presenters: Zlatan Coralic, PharmD; Bryan Hayes, PharmD, DABAT; Paul Takamoto, PharmD

### **Learning Objectives:**

- Describe different therapeutic options with a patient presenting with new onset atrial fibrillation.
- Evaluate the risks and benefits of utilizing procainamide for chemical cardioversion.
- Assess the risks of stroke and harm of anticoagulation for a patient presenting with a new onset atrial fibrillation

## **Meeting the Challenge: Caring for Patient with Ebola Virus Disease**

Tuesday, December 9, 2014

9:30 AM-11:00 AM

Activity #0204-0000-14-368-L01-P/0204-0000-14-368-L01-T

Level of Content: General Interest

1.50 Contact Hours/Knowledge-based

Room: 304B, Level 3

### **Learning Objectives:**

- Describe presenting symptoms of Ebola virus disease.
- Discuss how pharmacy should prepare for patients with suspected or confirmed infection.
- List clinical concerns related to caring for an infected patient.
- List non-clinical concerns related to caring for an infected patient.
- Describe the role of experimental medications for the treatment of Ebola virus disease.

## **Surviving Sepsis Campaign Guidelines Updates**

Tuesday, December 9, 2014

9:45 AM-11:00 AM

Activity #0204-0000-14-263-L01-P

Level of Content: Advanced

1.25 Contact Hours/Application-based

Room: Ballroom D, Level 3

Presentors: Kevin Anger, PharmD, BCPS

### **Learning Objectives:**

- Evaluate recent literature on the management of sepsis.
- Apply new and potentially controversial recommendations from the Surviving Sepsis Guidelines to patient cases.

## **Painful Prescriptions: To Fill or NOT to Fill, That is the Question**

Tuesday, December 9, 2014

2:00 PM-3:00 PM

Activity #0204-0000-14-294-L03-P/0204-0000-14-294-L03-T

Level of Content: General Interest

1.00 Contact Hours/Knowledge-based

Room: Ballroom A, Level 3

Presentors: Karen Ryle, MS, RPh

### **Learning Objectives:**

- Describe how the DEA has held pharmacists and pharmacies accountable for failing to verify prescriptions written for controlled substance for a legitimate medical purpose.
- Identify red flags that may appear when a patient presents with a prescription for controlled substance.
- Distinguish prescriptions that are being issued for a legitimate medical purpose from those that are not.
- Describe regulatory requirements that are affecting the prescribing and dispensing of controlled substances.

## **Clinical Pearls 2014**

Tuesday, December 9, 2014

2:00 PM-4:00 PM

Activity #0204-0000-14-201-L01-P

Level of Content: General Interest

2.00 Contact Hours/Knowledge-based

Room: Ballroom D, Level 3

Program Chair: Kim Benner, PharmD, BCPS, FASHP

Moderator: Bruce Canaday, BS, PharmD, FASHP

### **Learning Objectives:**

- Discuss three clinical scenarios that might not be widely known or published.
- Identify novel clinical practice options for patient care in various health-system settings.
- Describe medication management strategies in difficult or controversial patient care situations.
- Identify clinical information that can be applied to your work setting.



## **Tox Tale Trio – Prescription Drugs, Occupational Hazards, and Household Toxic Exposures**

Tuesday, December 9, 2014

2:00 PM-3:30 PM

Activity #0204-0000-14-267-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: Platinum 6, Anaheim Marriott, Lobby Level

Presenters: Christopher Edwards, PharmD, BCPS; Megan Musselman, PharmD, MS, BCPS; Suprat Wilson, PharmD, BCPS

### **Learning Objectives:**

- Identify common signs symptoms associated with prescription drugs, occupational hazards, and household agents.
- Describe antidotes used to treat specific toxidromes including calcium channel blockers and cyanide poisoning.
- Recommend a treatment regimen for a patient with household chemical exposure, including drain cleaner and laundry detergent pods.
- Develop treatment recommendations and monitoring for patients presenting with cyanide and pesticide poisoning.
- Create treatment plans for prescription drug overdoses including digoxin, calcium channel and beta blockers.

## **Professional Posters and ASHP Fellows**

Tuesday, December 9, 2014

02:30 PM-4:30 PM

Location: Hall E, Level 0 (Lower Level)

## **Management Case Study: Around the Clock Advanced Pharmacy Practice Experience: Utilizing Student Pharmacists in a Pediatric Emergency Department to Expand Clinical Services**

Tuesday, December 9, 2014

3:30 PM-4:00 PM

Activity #0204-0000-14-247-L04-P

Level of Content: General Interest

0.50 Contact Hours/Knowledge-based

Room: 209A, Level 2

Presenters: Ean Miller, PharmD; Ozioma Ogbuokiri, PharmD

### **Learning Objectives:**

- Describe the barriers to pharmacy-directed medication reconciliation through the continuum of care.
- List benefits of integrating learners into patient care duties.
- Identify potential challenges and solutions of implementing a new student rotation.

## **Defining Clinically Relevant Drug Interactions**

Tuesday, December 9, 2014

4:15 PM-5:15 PM

Activity #0204-0000-14-271-L01-P

Level of Content: Intermediate

1.00 Contact Hours/Application-based

Room: Platinum 6, Anaheim Marriott, Lobby Level

Presenters: John Horn, PharmD, FCCP; Daniel Malone, RPh, PhD; Jeremiah Momper, PharmD, PhD

### **Learning Objectives:**

- Explain the importance of a systematic method to evaluate drug interaction evidence.
- Interpret a case study in light of other evidence to determine if a drug interaction is clinically relevant.
- Using the DRIVE instrument, evaluate the evidence for a clinically relevant drug interaction.

## **Wednesday, December 10, 2014**

### **Emergency Medicine Pearls 2014**

Wednesday, December 10, 2014

8:00 AM-9:45 AM

Activity #0204-0000-14-204-L01-P

Level of Content: General Interest

1.75 Contact Hours/Knowledge-based

Room: Ballroom B, Level 3

Program Chair/Moderator: Christopher Edwards, PharmD, BCPS

### **Learning Objectives:**

- Discuss clinical practice in the Emergency Department.
- Explain applications of clinical pharmacotherapy in the Emergency Department.
- Discuss how to apply clinical pharmacotherapy to unique circumstances and clinical presentations.

### **Stress Ulcer Prophylaxis Updates and Guidelines**

Wednesday, December 10, 2014

8:00 AM-9:30 AM

Activity #0204-0000-14-273-L01-P

Level of Content: Advanced

1.50 Contact Hours/Application-based

Room: 304 B, Level 3

Presenters: Jeffrey Barletta, PharmD, FCCM; Mitchell Buckley, PharmD, FCCM, FASHP; Rob MacLaren, PharmD, FCCM

### **Learning Objectives:**

- Review the clinical efficacy, safety and pharmacoeconomic data for acid suppression agents.
- Evaluate stress-related mucosal disease risk factors and duration of prophylaxis.
- Recommend an evidence-based stress ulcer prevention strategy.

## **Results from the 2014 ASHP National Survey: The Current State of Pharmacy Practice in Hospitals**

Wednesday, December 10, 2014

2:00 PM-3:30 PM

Activity #0204-0000-14-342-L04-P

Level of Content: General Interest

1.50 Contact Hours/Knowledge-based

Room: 201B, Level 2

Presenters: Craig Pederson, PhD, FAPhA; Douglas Scheckelhoff, MS, FASHP; Philip Schneider, MS, FASHP

### **Learning Objectives:**

- Describe how the ASHP National Survey results can be used to effect change in your organization.
- List the most significant practice trends identified in the 2014 ASHP National Survey.
- Describe the practice trends that deviate from established best practices.

## **Bridging the Gap with Web 2.0 – Social Media in Pharmacy**

Wednesday, December 10, 2014

2:00 PM-3:30 PM

Activity #0204-0000-14-228-L04-P/0204-0000-14-228-L04-T

Level of Content: General Interest

1.50 Contact Hours/Application-based

Room: Ballroom A, Level 3

Presenters: Nadia Awad, PharmD, BCPS; Craig Cocchio, PharmD, BCPS; Kelly Grindrod, PharmD, MSc

### **Learning Objectives:**

- Analyze current trends associated with the use of social media in pharmacy.
- Design techniques in which social media can be incorporated into pharmacy education.
- Demonstrate ways in which social media can be used as a tool to further professional growth and clinical practice.

## **Patient Safety in Special Populations: Focus on Drug Dosing in Obesity**

Wednesday, December 10, 2014

2:00 PM-4:00 PM

Activity #0204-0000-14-274-L01-P

Level of Content: Advanced

2.00 Contact Hours/Application-based

Room: 303B, Level 3

Presenters: Jeffrey Barletta, PharmD, FCCM; Brian Erstad, PharmD, FASHP; Hanna Phan, PharmD, BCPS

### **Learning Objectives:**

- Assess patient characteristics that would ideally be included in equations involving size descriptors for medication dosing.
- Consider an approach for drug dosing in adult patients with more severe forms of obesity.
- Evaluate an approach for drug dosing in pediatric patients with more severe forms of obesity.

## **Does Your ED Really Stand for Error Department? Medication Error Mitigation in the ED**

Wednesday, December 10, 2014

4:00 PM-5:00 PM

Activity #0204-0000-14-206-L05-P

Level of Content: General Interest

1.00 Contact Hours/Knowledge-based

Room: 213B, Level 2

Presenters: Stephanie Baker Justice, PharmD; Kyle Weant, PharmD, BCPS

### **Learning Objectives:**

- Describe the medication-use process in the emergency department and identify the multiple medication error risk points.
- Evaluate potential strategies that can be implemented to help decrease medication errors and mitigate their impact on patient care.
- Discuss effective strategies for evaluating and analyzing medication errors so that their learning potential can be maximized.

## **Thursday, December 11, 2014**

## **No Hives About It: An Evidence-Based Approach to Managing Patients with a History of Drug Allergies**

Thursday, December 11, 2014

9:00 AM-10:00 AM

Activity #0204-0000-14-360-L01-P

Level of Content: Intermediate

1.00 Contact Hours/Application-based

Room: 209 A, Level 2

Presenters: Katelyn Dervay, PharmD, BCPS; Bryan Hayes, PharmD, DABAT; John Patka, PharmD

### **Learning Objectives:**

- Design an antimicrobial plan to include cephalosporins, given a patient with a documented penicillin allergy.
- Evaluate the risk of prescribing a sulfa-based, non-antimicrobial medication, given a patient with a listed sulfa antibiotic allergy.
- Evaluate the risk of prescribing an opiate or opioid medication, given a patient with a reported history of opiate allergy.
- Evaluate the risk of prescribing contrast media and alternative treatments, given a patient with a contrast media or iodine allergy.